Blood dyscrasias. Severe renal (including haemodialysis patients), and hepatic impairment (except in familial Mediterranean fever). Concomitant use with P-glycoprotein (P-gp) inhibitors or strong CYP3A4 inhibitors in patients with renal or hepatic impairment.